Status:
COMPLETED
CP-690,550 and Midazolam Drug-Drug Interaction Study
Lead Sponsor:
Pfizer
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam...
Eligibility Criteria
Inclusion
- Healthy male and/or female (non-child bearing potential) subjects
Exclusion
- Clinically significant infections within the past 3 months
- History of previously untreated infection with Mycobacterium tuberculosis
- Positive screening test for hepatitis B surface antigen, anti-hepatitis C antibody, or human immunodeficiency virus
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00902460
Start Date
June 1 2009
End Date
July 1 2009
Last Update
August 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511